Search Results - "Latifnia, Maryam"

Serum inflammatory markers in the elderly: are they useful in differentiating sepsis from SIRS? by Talebi-Taher, Mahshid, Babazadeh, Shahin, Barati, Mitra, Latifnia, Maryam

“…Differentiating sepsis from other noninfectious causes of systemic inflammation is often difficult in the elderly. The aim of this study was to evaluate the…”
Get full text

The efficient biogeneration of Ag and NiO nanoparticles from VPLE and a study of the anti-diabetic properties of the extract by Gao, Hongying, Tayebee, Reza, Abdizadeh, Mojtaba Fattahi, Mansouri, Esrafil, Latifnia, Maryam, Pourmojahed, Zahra

“…Vitex pseudo-negundo leaf extract (VPLE) is used to mediate the green biosynthesis of Ag and NiO nanoparticles in aqueous solutions under mild conditions. The…”
Get full text

SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial by Merat, Shahin

“…The combination of sofosbuvir and daclatasvir is a potent, pangenotypic regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited…”
Get full text

The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment by Poustchi, Hossein, Majd Jabbari, Sara, Merat, Shahin, Sharifi, Amir‐Houshang, Shayesteh, Ali Akbar, Shayesteh, Elahe, Minakari, Mohammad, Fattahi, Mohammad Reza, Moini, Maryam, Roozbeh, Fatemeh, Mansour‐Ghanaei, Fariborz, Afshar, Behrooz, Mokhtare, Marjan, Amiriani, Taghi, Sofian, Masoomeh, Somi, Mohammad‐Hossein, Agah, Shahram, Maleki, Iradj, Latifnia, Maryam, Fattahi Abdizadeh, Mojtaba, Hormati, Ahmad, Khoshnia, Masoud, Sohrabi, Masoudreza, Malekzadeh, Zeinab, Merat, Dorsa, Malekzadeh, Reza

“…Background and Aim Many of the treatment regimens available for hepatitis C include sofosbuvir. Unfortunately, sofosbuvir has not been recommended for use in…”
Get full text

Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial by Merat, Shahin, Sharifi, Amir-Houshang, Poustchi, Hossein, Hajiani, Eskandar, Gharavi, Abdolsamad, Karimi, Jalal, Mansour-Ghanaei, Fariborz, Fattahi, Mohammad-Reza, Ahmadi, Lida, Somi, Mohammad-Hossein, Kalantari, Hamid, Ghadir, Mohammad-Reza, Sheikhesmaeili, Farshad, Baniasadi, Nadieh, Sohrabi, Masoudreza, Moosavy, Seyedhamid, Ziaee, Masood, Zahedi, Mohammad-Javad, Mokhtare, Marjan, Sali, Shahnaz, Sayad, Babak, Afshar, Behrooz, Bakhshipour, Alireza, Parsi, Abazar, Sharifian, Afsaneh, Amiriani, Taghi, Malekzadeh, Zeinab, Merat, Dorsa, Ganji, Azita, Rahmani-Samani, Fereidoun, Jamali, Raika, Sofian, Masoomeh, Ghezlou, Mohammad, Sohrabpour, Amir Ali, Goshayeshi, Ladan, Valizadeh-Toosi, Seyed-Mohammad, Eslami, Layli, Maleki, Iradj, Hormati, Ahmad, Shayesteh, Ali-Akbar, Shayesteh, Elahe, Norouzi, Alireza, Abna, Zahra, Janbakhsh, Alireza, Fakheri, Hafez, Minakari, Mohammad, Sardarian, Hossein, Ghajary, Adel F Allah, Fattahi-Abdizadeh, Mojtaba, Latifnia, Maryam, Roozbeh, Fatemeh, Agah, Shahram, Fakhrieh-Asl, Saba, Nateghi-Baygi, Alireza, Fattahi, Babak, Nateghi-Baygi, Helia, Hill, Andrew, Malekzadeh, Reza

Get full text

THU-162-The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets by Merat, Shahin, Sharifi, Amir-Houshang, Shayesteh, Ali Akbar, Minakari, Mohammad, Fattahi, Mohammad Reza, Moini, Maryam, Roozbeh, Fatemeh, Mansour-Ghanaei, Fariborz, Afshar, Behrooz, Mokhtare, Marjan, Amiriani, Taghi, Sofian, Masomeh, Somi, Mohammad-Hossein, Agah, Shahram, Maleki, Iradj, Latifnia, Maryam, Hormati, Ahmad, Khoshnia, Masoud, Sohrabi, Masoud, Malekzadeh, Reza

Get full text